Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis

Clinical Neuropharmacology

Volumn 33, Issue 2, 2010, Pages 91-101

  Chun, Jerold ^a   Hartung, Hans Peter ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Fingolimod; Multiple sclerosis; Sphingosine 1 phosphate; Sphingosine 1 phosphate receptor modulator

Indexed keywords

BETA INTERFERON; FINGOLIMOD; PLACEBO; SPHINGOSINE 1 PHOSPHATE;

CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; GENE EXPRESSION; HUMAN; IMMUNE SYSTEM; LYMPHOCYTE FUNCTION; LYMPHOCYTE RECIRCULATION; MULTIPLE SCLEROSIS; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; CENTRAL NERVOUS SYSTEM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTES; MODELS, IMMUNOLOGICAL; MULTIPLE SCLEROSIS; NEUROGLIA; NEURONS; PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE;

EID: 77951073508     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181cbf825     Document Type: Review

References (127)

1. Confavreux C, Vukusic S. Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg 2006;108:327-332.
2. Noseworthy JH, Luchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med 2000;343:938-952.
3. World Health Organization. Neurology atlas. Available at: http://www.who.int/mental-health/neurology/ neurogy-atlas-review-.pdf. 2004. Accessed June 1, 2009.
4. Dev KK, Mullershausen F, Mattes H, et al. Brain sphingosine-1-phosphate receptors: implication for FT-720 in the treatment of multiple sclerosis. Pharmacol Ther 2008;117(1): 77-93.
5. Frohman EM, Racke MK, Raine CS. Multiple sclerosisVthe plaque and its pathogenesis. N Engl J Med 2006;354(9):942-955.
6. Odoardi F, Kawakami N, Klinkert WE, et al. Blood-borne soluble protein antigen intensifies T cell activation in autoimmune CNS lesions and exacerbates clinical disease. Proc Natl Acad Sci U S A 2007;104:18625-18630.
7. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338(5):278-285.
8. Peterson LK, Fujinami RS. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol 2007;184:37-44.
9. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359(9313):1221-1231.
10. Frohman EM, Filippi M, Stuve O, et al. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol 2005;62(9): 1345-1356.
11. Kerschensteiner M, Bareyre FM, Buddeberg BS, et al. Remodeling of axonal connections contributes to recovery in an animal model of multiple sclerosis. J Exp Med 2004;200(8):1027-1038.
12. Hemmer B, Hartung HP. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol 2007;62:314-326.
13. Virley DJ. Developing therapeutics for the treatment of multiple sclerosis. NeuroRx 2005;2(4):638-649.
14. Association of British Neurologists. ABN guidelines for treatment of multiple sclerosis with A-interferons and glatiramer acetate. Available at: http://www.theabn.org/downloads/ ABN-MS-Guidelines-2007.pdf. 2007. Accessed June 1, 2009.
15. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58(2):169-178.
16. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol 2007;6:903-912.
17. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354(9):899-910.
18. Natalizumab. Summary of Product Characteristics Biogen idec Inc. Available at: http://emc.medicines.org.uk/medicine/18447/SPC/ TYSABRI+300+mg+concentrate+for+solution+for+infusion/. 2009. Accessed December 11, 2009.
19. Natalizumab. Prescribing information EMD Serono Inc. Available at: http://www.biogenidec.com/site/TYSABRI-PI-MedGuide.pdf. 2006. Accessed December 11, 2009.
20. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353(4):369-374.
21. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353(4):375-381.
22. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumabYunforeseen consequences. N Engl J Med 2005;353(4):414-416.
23. Mitoxantrone. Prescribing information EMD Serono Inc. Available at: http://www.novantrone.com/assets/pdf/ novantrone-prescribing-info.pdf. 2008. Accessed December 11, 2009.
24. Samuel L, Lowenstein EJ. Recurrent injection site reactions from interferon beta 1-b. J Drugs Dermatol 2006;5(4):366-367.
25. Langer-Gould A, Moses HH, Murray TJ. Strategies for managing the side effects of treatments for multiple sclerosis. Neurology 2004;63 (11 suppl 5):S35-S41.
26. Cox D, Stone J. Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis. J Neurosci Nurs 2006;38(3): 167-171.
27. World Health Organization. Adherence to long-term therapies: evidence for action. Available at: http://www.who.int/chp/knowledge/ publications/adherence- introduction.pdf. 2003. Accessed December 11, 2009.
28. Cohen BA, Rieckmann P. Emerging oral therapies for multiple sclerosis. Int J Clin Pract 2007;61(11):1922-1930.
29. Baumruker T, Billich A, Brinkmann V. FT-720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opin Investig Drugs 2007;16(3):283-289.
30. Adachi K, Chiba K. FT-720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology. Perspect Medicin Chem 2007;1:11-23.
31. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FT-720) for relapsing multiple sclerosis. N Engl JMed 2006;355(11):1124-1140.
32. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003;4(5):397-407.
33. Fukushima N, Ishii I, Contos JJ, et al. Lysophospholipid receptors. Annu Rev Pharmacol Toxicol 2001;41:507-534.
34. Anliker B, Chun J. Lysophospholipid G protein-coupled receptors. J Biol Chem 2004;279(20):20555-20558.
35. Ishii I, Fukushima N, Ye X, et al. Lysophospholipid receptors: signaling and biology. Annu Rev Biochem 2004;73:321-354.
36. Chun J. How the lysophospholipid got its receptor. Scientist 2007;21:48-54.
37. Chun J. Immunology. The sources of a lipid conundrum. Science 2007;316(5822):208-210.
38. Mandala S, Hajdu R, Bergstrom J, et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002;296(5566):346-349.
39. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007;115(1):84-105.
40. Brinkmann V, Cyster JG, Hla T. FT-720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004;4(7):1019-1025.
41. Toman RE, Payne SG, Watterson KR, et al. Differential transactivation of sphingosine-1-phosphate receptors modulates NGF-induced neurite extension. J Cell Biol 2004;166(3):381-392.
42. Pyne S, Pyne N. Sphingosine 1-phosphate signalling via the endothelial differentiation gene family of G-protein-coupled receptors. Pharmacol Ther 2000;88(2):115-131.
43. Pyne S, Pyne NJ. Sphingosine 1-phosphate signalling in mammalian cells. Biochem J 2000;349(pt 2):385-402.
44. Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science 2007;316(5822):295-298.
45. Gardell SE, Dubin AE, Chun J. Emerging medicinal roles for lysophospholipid signaling. Trends Mol Med 2006;12(2):65-75.
46. Herr DR, Chun J. Effects of LPA and S1P on the nervous system and implications for their involvement in disease. Curr Drug Targets 2007;8(1):155-167.
47. Gardell S, Choi JW, Anliker B, et al. Evidence for neural S1P receptor signaling in EAE and FT-720 efficacy. Mult Scler 2007;13:S70.
48. Webb M, Tham CS, Lin FF, et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol 2004;153(1-2):108-121.
49. Wheeler D, Bandaru VV, Calabresi PA, et al. A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain 2008;131(pt 11):3092-3102.
50. Zhang G, Contos JJ, Weiner JA, et al. Comparative analysis of three murine G-protein coupled receptors activated by sphingosine-1-phosphate. Gene 1999;227(1):89-99.
51. Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem 2004;92(5):913-922.
52. Chun J. Lysophospholipid receptors: implications for neural signaling. Crit Rev Neurobiol 1999;13(2):151-168.
53. Chun J, Contos JJ, Munroe D. A growing family of receptor genes for lysophosphatidic acid (LPA) and other lysophospholipids (LPs). Cell Biochem Biophys 1999;30(2):213-242.
54. Chun J, Weiner JA, Fukushima N, et al. Neurobiology of receptor-mediated lysophospholipid signaling. From the first lysophospholipid receptor to roles in nervous system function and development. Ann N Y Acad Sci 2000;905:110-117.
55. Chun J. Lysophospholipids in the nervous system. Prostaglandins Other Lipid Mediat 2005;77(1-4):46-51.
56. Mutoh T, Chun J. Lysophospholipid activation of G protein-coupled receptors. Subcell Biochem 2008;49:269-297.
57. Rivera R, Chun J. Biological effects of lysophospholipids. Rev Physiol Biochem Pharmacol 2008;160:25-46.
58. Watterson K, Sankala H, Milstien S, et al. Pleiotropic actions of sphingosine-1-phosphate. Prog Lipid Res 2003;42(4):344-357.
59. Miron VE, Jung CG, Kim HJ, et al. FT-720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008;63(1):61-71.
60. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004;427(6972):355-360.
61. Jaillard C, Harrison S, Stankoff B, et al. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J Neurosci 2005;25(6):1459-1469.
62. Kimura A, Ohmori T, Ohkawa R, et al. Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 2007;25(1):115-124.
63. Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 2007;8(12):1295-1301.
64. Mizugishi K, Yamashita T, Olivera A, et al. Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 2005;25(24):11113-11121.
65. de Sampaio ESTC, Choi JW, Gardell SE, et al. Lysophosphatidic acid receptor-dependent secondary effects via astrocytes promote neuronal differentiation. J Biol Chem 2008;283(12):7470-7479.
66. Gergely P, Wallström E, Nuesslein-Hildesheim B, et al. Phase I study with the selective S1P1/S1P5 receptor modulator BAF312 indicates that S1P1 rather than S1P3 mediates transient heart rate reduction in humans. Mult Scler 2009;15:S125.
67. Brinkmann V, Baumruker T. Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Curr Opin Pharmacol 2006;6(3):244-250.
68. Nofer JR, Bot M, Brodde M, et al. FT-720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007;115(4):501-508.
69. Billich A, Bornancin F, Devay P, et al. Phosphorylation of the immunomodulatory drug FT-720 by sphingosine kinases. J Biol Chem 2003;278(48):47408-47415.
70. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FT-720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002;277(24):21453-21457.
71. Pinschewer DD, Ochsenbein AF, Odermatt B, et al. FT-720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000;164(11):5761-5770.
72. Mehling M, Brinkmann V, Antel J, et al. FT-720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008;71(16):1261-1267.
73. Mehling M, Lindberg R, Kuhle J, et al. Oral fingolimod (FT-720) treatment reduces peripheral IL-17-producing TH17 cells in patients with multiple sclerosis. Mult Scler 2008;14:S234.
74. Oo ML, Thangada S, Wu MT, et al. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem 2007;282(12):9082-9089.
75. Graler MH, Goetzl EJ. The immunosuppressant FT-720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J 2004;18(3):551-553.
76. Fujino M, Funeshima N, Kitazawa Y, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FT-720 treatment. J Pharmacol Exp Ther 2003;305(1):70-77.
77. Brinkmann V, Metzler B, Matloubian M, et al. The mode of action of fingolimod (FT-720), an oral sphingosine 1-phosphate receptor modulator that is highly effective in human multiple sclerosis (phase II). Mult Scler 2006;12:S100.
78. Tzartos JS, Friese MA, Craner MJ, et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008;172(1):146-155.
79. Kebir H, Kreymborg K, Ifergan I, et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med 2007;13(10):1173-1175.
80. Masopust D, Vezys V, Marzo AL, et al. Preferential localization of effector memory cells in nonlymphoid tissue. Science 2001; 291(5512):2413-2417.
81. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401(6754):708-712.
82. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-763.
83. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003;3(4):269-279.
84. Hofmann M, Brinkmann V, Zerwes HG. FT-720 preferentially depletes naive T cells from peripheral and lymphoid organs. Int Immunopharmacol 2006;6(13-14):1902-1910.
85. Schmouder R, Aradhye S, O'Connor P, et al. Pharmacodynamic effects of oral fingolimod (FT-720). Mult Scler 2006;12(suppl 1):S101.
86. Westermann J, Pabst R. Distribution of lymphocyte subsets and natural killer cells in the human body. Clin Investig 1992; 70(7):539-544.
87. Brinkmann V, Chen S, Feng L, et al. FT-720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transplant Proc 2001;33(1-2):530-531.
88. Xie JH, Nomura N, Koprak SL, et al. Sphingosine-1-phosphate receptor agonism impairs the efficiency of the local immune response by altering trafficking of naive and antigen-activated CD4+ T cells. J Immunol 2003;170(7):3662-3670.
89. Metzler B, Gfeller P, Wieczorek G, et al. Modulation of T cell homeostasis and alloreactivity under continuous FT-720 exposure. Int Immunol 2008;20(5):633-644.
90. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FT-720) in relapsing ms: 24-month results of the phase II study. Mult Scler 2006; 12:S101.
91. Yopp AC, Fu S, Honig SM, et al. FT-720-enhanced T cell homing is dependent on CCR2, CCR5, CCR7, and CXCR4: evidence for distinct chemokine compartments. J Immunol 2004;173(2):855-865.
92. Kursar M, Janner N, Pfeffer K, et al. Requirement of secondary lymphoid tissues for the induction of primary and secondary T cell responses against Listeria monocytogenes. Eur J Immunol 2008;38(1):127-138.
93. Foster CA, Howard LM, Schweitzer A, et al. Brain penetration of the oral immunomodulatory drug FT-720 and its phosphorylation in the CNS during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 2007;323(2):469-475.
94. Birgbauer E, Chun J. New developments in the biological functions of lysophospholipids. Cell Mol Life Sci 2006;63(23):2695-2701.
95. Chun J, Rosen H. Lysophospholipid receptors as potential drug targets in tissue transplantation and autoimmune diseases. Curr Pharm Des 2006;12(2):161-171.
96. McGiffert C, Contos JJ, Friedman B, et al. Embryonic brain expression analysis of lysophospholipid receptor genes suggests roles for s1p(1) in neurogenesis and s1p(1-3) in angiogenesis. FEBS Lett 2002;531(1):103-108.
97. Herr DR, Grillet N, Schwander M, et al. Sphingosine 1-phosphate (S1P) signaling is required for maintenance of hair cells mainly via activation of S1P2. J Neurosci 2007;27(6):1474-1478.
98. Miron VE, Schubart A, Antel JP. Central nervous system-directed effects of FT-720 (fingolimod). J Neurol Sci 2008;274(1-2):13-17.
99. Saini HS, Coelho RP, Goparaju SK, et al. Novel role of sphingosine kinase 1 as a mediator of neurotrophin-3 action in oligodendrocyte progenitors. J Neurochem 2005;95(5):1298-1310.
100. Novgorodov AS, El-Alwani M, Bielawski J, et al. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J 2007;21(7):1503-1514.
101. Barske C, Osinde M, Mir AK, et al. FT-720 (fingolimod) enhances the number of progenitor and mature oligodendrocytes. Mult Scler 2007;13:S148.
102. Coelho RP, Payne SG, Bittman R, et al. The immunomodulator FT-720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 2007;323(2):626-635.
103. Harada J, Foley M, Moskowitz MA, et al. Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J Neurochem 2004;88(4):1026-1039.
104. Edsall LC, Pirianov GG, Spiegel S. Involvement of sphingosine 1-phosphate in nerve growth factor-mediated neuronal survival and differentiation. J Neurosci 1997;17(18):6952-6960.
105. Chin TY, Hwang HM, Chueh SH. Distinct effects of different calcium-mobilizing agents on cell death in NG108-15 neuroblastoma X glioma cells. Mol Pharmacol 2002;61(3):486-494.
106. Shinpo K, Kikuchi S, Moriwaka F, et al. Protective effects of the TNF-ceramide pathway against glutamate neurotoxicity on cultured mesencephalic neurons. Brain Res 1999;819(1-2):170-173.
107. Deogracias R, Matsumoto T, Klein C, et al. FT-720 induces BDNF production in neuronal cell cultures. Neurology 2008;70:A373.
108. Balatoni B, Storch MK, Swoboda EM, et al. FT-720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 2007;74(5):307-316.
109. Deogracias R, Klein C, Matsumoto T, et al. Expression of brain-derived neutrophic factor is regulated by FT-720 in cultured neurons. Mult Scler 2008;14:S243.
110. Giovannoni G, Al-Izki S, Pryce G, et al. Control of chronic relapsing progressive EAE with fingolimod. In: AAN: 60th Annual Meeting of the American Academy of Neurology. Chicago, IL: Poster; 2008: 12-17.
111. Nair A, Frederick TJ, Miller SD. Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci 2008;65(17): 2702-2720.
112. Pekny M, Nilsson M. Astrocyte activation and reactive gliosis. Glia 2005;50(4):427-434.
113. Sorensen SD, Nicole O, Peavy RD, et al. Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol Pharmacol 2003;64(5):1199-1209.
114. Rao TS, Lariosa-Willingham KD, Lin FF, et al. Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes. Brain Res 2003;990 (1-2):182-194.
115. Mullershausen F, Craveiro LM, Shin Y, et al. Phosphorylated FT-720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J Neurochem 2007;102(4):1151-1161.
116. Rao TS, Lariosa-Willingham KD, Lin FF, et al. Growth factor pre-treatment differentially regulates phosphoinositide turnover downstream of lysophospholipid receptor and metabotropic glutamate receptors in cultured rat cerebrocortical astrocytes. Int J Dev Neurosci 2004;22(3):131-135.
117. Yamagata K, Tagami M, Torii Y, et al. Sphingosine 1-phosphate induces the production of glial cell line-derived neurotrophic factor and cellular proliferation in astrocytes. Glia 2003;41(2):199-206.
118. Osinde M, Mullershausen F, Dev KK. Phosphorylated FT-720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology 2007;52(5):1210-1218.
119. Kappos L, Cohen J, Pelletier J, et al. Safety findings from a 12-month phase III study (TRANSFORMS) comparing oral fingolimod (FT-720) and intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis. Mult Scler 2009;15:S245.
120. Cohen J, Pelletier J, Kappos L, et al. Oral fingolimod (FT-720) significantly reduced relapse rate compared with intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: clinical results from a 12-month phase III study (TRANSFORMS). Mult Scler 2009;15:S132.
121. Barkhof F, Cohen J, Comi G, et al. Oral fingolimod (FT-720) significantly reduced MRI inflammatory activity compared with intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: MRI findings from a 12-month phase III study (TRANSFORMS). Mult Scler 2009;15:S21.
122. Kataoka H, Sugahara K, Shimano K, et al. FT-720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2005;2(6):439-448.
123. Foster CA, Mechtcheriakova D, Storch MK, et al. FT-720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain barrier damage. Brain Pathol 2009;19(2):254-266.
124. Schubart A, Howard LM, Seabrook T, et al. FT-720 suppresses ongoing EAE and promotes a remyelinating environment preventing axonal degeneration within the CNS. Neurology 2008;70:A339.
125. Montalban X, O'Connor P, Antel J, et al. Oral fingolimod (FT-720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: 4-year results from a phase II extension. Neurology 2009;72:A313.
126. Koyrakh L, Roman MI, Brinkmann V, et al. The heart rate decrease caused by acute FT-720 administration is mediated by the G proteinYgated potassium channel I. Am J Transplant 2005;5(3): 529-536.
127. Choi JW, Lee CW, Chun J. Biological roles of lysophospholipid receptors revealed by genetic null mice: an update. Biochim Biophys Acta 2008;1781(9):531-539.